Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?

Am J Gastroenterol. 2024 Aug 1;119(8):1644. doi: 10.14309/ajg.0000000000002766. Epub 2024 Mar 14.

Authors

Simon John Hume^{1

2

3}, Jacinta Alison Holmes^{1

2}, Alexander James Thompson^{1

2}

Affiliations

¹ St Vincent's Hospital Melbourne, Melbourne, Australia.
² University of Melbourne, Melbourne, Australia.
³ Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital and Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia .

PMID: 38619141
DOI: 10.14309/ajg.0000000000002766

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents* / administration & dosage
Antiviral Agents* / therapeutic use
Hepatitis B Surface Antigens* / blood
Hepatitis B virus
Hepatitis B, Chronic* / drug therapy
Humans
Nucleosides / administration & dosage
Nucleosides / therapeutic use

Substances

Antiviral Agents
Hepatitis B Surface Antigens
Nucleosides